Dr. Yilin Zhang currently works as a physician at a residency program in Huashan Hospital Affiliated to Fudan University in Shanghai, China. Her research interests include clinical trials of novel treatment regimens and treatment safety in rifampicin-resistant tuberculosis patients, especially in RR-TB patients experiencing other comorbidities such as diabetes mellitus and undernutrition.
A large-scale study found that varying doses of linezolid, ranging from 600mg daily for 9 months to 300mg daily for 7 months, were effective in treating rifampicin-resistant tuberculosis with high success rates and minimal severe adverse effects, including anemia and peripheral neuropathy.
Source: Conference 2024Poor glycemic control during rifampicin-resistant TB treatment in diabetic patients significantly reduces treatment success rates, emphasizing the importance of optimized diabetes management in improving outcomes.
Source: Conference 2024A novel blood-based 3-gene signature score shows promise for monitoring rifampicin-resistant tuberculosis treatment, demonstrating strong predictive performance for early culture conversion.
Source: Conference 2024The current study showed the bedaquiline/levofloxacin/clofazimine group had the greatest QTcF prolongation risk, warranting enhanced monitoring in such drug combinations.
Source: Conference 2024